Cargando…

POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy

OBJECTIVE: Although Polymerase-epsilon (POLE)-mutated and mismatch repair (MMR)-deficient endometrial cancers (ECs) are considered as promising candidates for anti-PD-1/PD-L1 therapy, selecting only these patients may exclude other patients who could potentially respond to this treatment strategy, h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Dandan, Lei, Huajiang, Liu, Duanya, Bai, Hansong, Yang, Yue, Tang, Baijie, Li, Ke, Liu, Juan, Xu, Gang, Xiao, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017289/ https://www.ncbi.nlm.nih.gov/pubmed/33816285 http://dx.doi.org/10.3389/fonc.2021.640018

Ejemplares similares

Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
por: Jimenez-Rodriguez, Rosa M., et al.
Publicado: (2020)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
por: Kepp, Oliver, et al.
Publicado: (2023)

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

POLE/POLD1 mutation and tumor immunotherapy
por: Ma, Xiaoting, et al.
Publicado: (2022)

Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
por: Mestrallet, Guillaume, et al.
Publicado: (2023)

Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status
por: Kong, Pengfei, et al.
Publicado: (2019)

Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer
por: Shigaki, Takahiro, et al.
Publicado: (2022)

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes
por: Kim, Jin K., et al.
Publicado: (2022)

Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers
por: Yoon, Harry H., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
por: Rizzo, Alessandro
Publicado: (2022)

Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma
por: Jung, In Kook, et al.
Publicado: (2014)

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer
por: Gulhan, Doga C., et al.
Publicado: (2020)

The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications
por: Yang, Liu, et al.
Publicado: (2021)

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
por: Zhu, Jingjing, et al.
Publicado: (2017)

Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma
por: Vermeulen, Jeroen F., et al.
Publicado: (2017)

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
por: Hasan Ali, Omar, et al.
Publicado: (2020)

Single-Cell Profiling of the Immune Atlas of Tumor-Infiltrating Lymphocytes in Endometrial Carcinoma
por: Jiang, Fang, et al.
Publicado: (2022)

Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy
por: Bai, Ziyi, et al.
Publicado: (2022)

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade
por: Duraiswamy, Jaikumar, et al.
Publicado: (2013)

Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
por: Kodumudi, Krithika N., et al.
Publicado: (2016)

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
por: Plesca, Ioana, et al.
Publicado: (2020)

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
por: Auclin, Edouard, et al.
Publicado: (2021)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer
por: Fan, Chun-Ting, et al.
Publicado: (2023)

Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair–deficient tumors
por: Takahashi, Nobuyuki, et al.
Publicado: (2020)

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
por: Sena, Laura A., et al.
Publicado: (2020)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
por: Wang, Shuhang, et al.
Publicado: (2021)

The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
por: Liu, Dong, et al.
Publicado: (2022)

Tumor infiltrating lymphocytes and radiological picture of the tumor
por: Frankowska, Karolina, et al.
Publicado: (2023)

Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status
por: Sawada, Kiyoka, et al.
Publicado: (2023)

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report
por: Rey-Cárdenas, Macarena, et al.
Publicado: (2023)

Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
por: Wu, Wantao, et al.
Publicado: (2021)

Adoptive cell therapy using tumor‐infiltrating lymphocytes for melanoma refractory to immune‐checkpoint inhibitors
por: Hirai, Ikuko, et al.
Publicado: (2021)

Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer
por: Qin, Miao, et al.
Publicado: (2023)

Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency
por: Lindsay, Holly, et al.
Publicado: (2019)

Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer
por: Huang, He, et al.
Publicado: (2022)

Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
por: Bellone, Matteo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kbp3mu99fj3sckk79a8ctdhr50